Kornimate/medical-research-clean huggingface dataset:
effect of omega 3 on periodontitis in postmenopausal women

Conditions: Chronic Periodontitis

Summary: the study was aimed to investigating changes in periodontal parameters and superoxide dismutase activity after root surface debridement with and without omega 3 fatty acids (ω-3 fas) supplementation in postmenopausal women. adjunctive omega 3 fatty acids supplements reduce periodontal inflammation and improve the status of systemic enzymatic antioxidants in postmenopausal women.

fifty postmenopausal women with chronic periodontitis were divided randomly into two groups: group 1 (n=25) were provided periodontal treatment in the form of scaling and root planing (srp) plus placebo soft gelatin capsules while group 2 (n=25): patients were received srp along with systemic administration of omega 3 fatty acids. clinical parameters and superoxide dismutase (sod) activity in the gingival crevicular fluid were recorded at baseline, 3 and 6 months after therapy. the research has been conducted between july 2014 and june 2015. by the end of the study period, the omega 3 treated group was able to achieve a greater mean probing pocket depth reduction, mean gain in clinical attachment level, as well as greater increase in sod activity (p\<0.01) compared to srp alone.

Eligibility criteria:
inclusion criteria: * postmenopausal women with generalized chronic periodontitis (clinical attachment loss more than 30% of the teeth) * with probing pocket depth ≥ 5mm. * the age ranged between 45 and 60 years (to avoid the wide variation between individual cases in order to make the sample more homogeneous. furthermore elderly patients above 60 years are usually not willing to have periodontal treatment). * postmenopausal status for at least 1 year. * presence of at least six teeth in the mouth. exclusion criteria: * any systemic disease that affect the periodontium. * women who take anti-inflammatory drugs, antibiotics or vitamins within the previous 3 month. * women who use mouth washes regularly * smoking * history of alcohol abuse * participation in other clinical trials. * obese women (body mass index (bmi) ≥ 30).

Keywords: omega 3 fatty acids root planning chronic periodontitis
safety and efficacy study of apd125 in patient with insomnia

Conditions: Insomnia

Summary: the purpose of this study is to determine the effects of apd125 in patients with sleep maintenance insomnia.


Eligibility criteria:
inclusion criteria: * primary insomnia as defined in dsm-iv-tr, with predominant complaint of impaired sleep maintenance and confirmed by psg * psqi \>/= to 5 * qualifying screening psg parameters * generally good health exclusion criteria: * history of any sleep disorder, other than primary insomnia (e.g., restless leg syndrome, narcolepsy, sleep apnea, and disorders of rem/nrem sleep) * any clinically significant medical condition, laboratory finding, or ecg finding * pregnant and/or lactating females * history of substance abuse within 2 years or positive urine drug screen * positive hepatitis b/c results or hiv markers * apnea-hypopnea index (ahi) or a periodic limb movement arousal index (plmai) \> 10 as determined by screening psg * history of treatment with an investigational drug within the last month * recent travel involving crossing more than 3 time zones or plans to travel to another time zone (\> 3 time zones) during the study

Keywords: sleep maintenance insomnia sleep consolidation sleep insomnia, primarily sleep maintenance
comparison of sedative effect of dexmedetomidine and midazolam for tiva

Conditions: Choosing Better Drug Option for Sedation in Pediatric Population Intraoperatively

Summary: comparison of sedative effects of dexmedetomidine and midazolam using ramsay sedation scores intraoperatively in children undergoing inguinal hernia repair.

a randomized controlled trial to compare the sesative effects of dexmedetomidine and midazolam in pediatric population planned for inguinal herna repair under tiva in sheikh zayed hospital rahim yar khan.

Eligibility criteria:
inclusion criteria: * asa i and ii age 6 to 12 years any gender exclusion criteria: * asa iii and above age less than 2 years and above 12 years congenital heart disease cardiac arrythmias congenital abnormalities respiratory disease endocrine disorders mental retardation organ dysfunction bleeding disorders physician or family refusal previous surgeries allergy to any drug
deep brain stimulation in patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is to determine the effect of deep brain stimulation surgery on movement-related cortical potentials in patients with parkinson's disease.

patients who have had deep brain stimulation surgery for parkinson's disease at mayo clinic arizona will have electroencephalographic (eeg) measurements with the stimulator on followed by eeg measurements with the stimulator off. patients who are scheduled to have deep brain stimulation surgery for parkinson's disease will have eeg measurements before and after surgery.

Eligibility criteria:
inclusion criteria: * patients who have had deep brain stimulation surgery for parkinson's disease at mayo clinic arizona, or who are scheduled to have deep brain stimulation surgery for parkinson's disease at mayo clinic arizona. exclusion criteria: * patients unable to do repetitive dorsiflexion of the wrist due to orthopedic problems. * pregnant women. * prisoners or institutionalized individuals.
a study of aripiprazole lauroxil or paliperidone palmitate for the treatment of schizophrenia

Conditions: Schizophrenia

Summary: this study will evaluate the efficacy of initiating treatment of schizophrenia with aristada initio plus 30 mg oral aripiprazole followed by a 2-month dose of al.


Eligibility criteria:
inclusion criteria: * has a diagnosis of schizophrenia * requires acute treatment for symptoms of schizophrenia * willing and able to be confined to an inpatient study unit for up to 3-4 weeks * has experienced at least one previous hospitalization for schizophrenia * has been able to achieve outpatient status for more than 3 months in the past year * has a body mass index (bmi) between 18.0 and 40.0 kg/m\^2 * resides in a stable living situation when not hospitalized * has an identified reliable caregiver (for example, family member) * additional criteria may apply exclusion criteria: * poses a current suicide risk * pregnant, planning to become pregnant, or breastfeeding * initiated first antipsychotic treatment within the past 12 months * has received a long-acting injectable antipsychotic in the past 3 months * has participated in a clinical study involving any investigational product within the past 3 months, or is currently participating in a clinical study involving an investigational product. * a positive urine drug test for drugs of abuse * additional criteria may apply

Keywords: alkermes schizophrenia aripiprazole lauroxil aristada aristada initio
cognitive behavioral therapy (cbt) study evaluating the updating of persecutory beliefs

Conditions: Schizophrenia; Psychosis; Persecutory Delusion

Summary: the purpose of this study is to examine how bayesian belief updating changes throughout psychotherapeutic treatment for persecutory delusions. specifically, individuals with a psychotic disorder diagnosis who endorse both a current persecutory delusion with strong conviction and significant worry will be recruited and randomized to receive either a cbt-based worry intervention for persecutory delusions or an active control condition (befriending therapy). the investigators will examine: 1) whether belief updating parameters change as delusion severity changes, 2) whether cbt contributes to greater change in belief updating parameters than befriending therapy, and 3) whether neural correlates of belief updating parameters, as measured using functional magnetic resonance imaging (fmri), predict treatment response.


Eligibility criteria:
inclusion criteria: 1. men and women age 18 - 65. 2. communicative in english. 3. premorbid intelligence \>79 (wtar) 4. provide voluntary, written informed consent. 5. physically healthy by medical history. 6. weight \<300 lbs 7. stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication. 8. diagnosis of a non-affective psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, psychosis nos) confirmed by structured clinical interview for diagnostic and statistical manual (dsm)-5 (scid) or diagnostic interview with a trained clinician. 9. a persecutory delusion scoring at least a 3 on the conviction scale of the psychotic symptoms rating scale (psyrats) that had persisted for at least two weeks and that was not considered the direct result of substance use 10. a clinically significant level of worry, as shown by a score of at least 44 on the penn state worry questionnaire (pswq). exclusion criteria: 1. age less than 18 or greater than 65. 2. not communicative in english. 3. premorbid iq \< 79 (wtar) 4. unable to provide written informed consent. 5. current medical or neurological illness. 6. history of severe head trauma. 7. weight \>300 lbs 8. primary diagnosis of alcohol or substance use disorder or personality disorder 9. conditions that preclude fmri scanning (as defined in the fmri screening form) 10. subjects who are actively involved with individual cognitive therapy (past experience with individual therapy is not an exclusion)
cold snare polypectomy of non-pedunculated colorectal adenomas

Conditions: Colorectal Polyp

Summary: a prospective randomised controlled trial of cold vs hot snare polypectomy of non-pedunculated colorectal adenomas.

diagnostic colonoscopy will be performed in all patients. if a polyp, appropriate for inclusion criteria, is identified, an endoscopic polypectomy will be assigned. all eligible polyps will be randomly assigned (1:1) to endoscopic polypectomy with either the cold snare resection or hot snare resection (control group). randomization will be stratified using random numbers. after resection, the marginal mucosa will be carefully observed with used of magnification and image enhancement (near focus imaging or narrow band imaging) for determine residual tissue. the time period when the snare will be entered in the bowel lumen and until a polyp will be retrieved will be recorded by a stopwatch. all polyps will be retrieved for morphological examination to estimate r0/r1resetion. after polypectomy all patients will be observed for 3-4 days in-hospital to diagnose and eliminate complications (delayed bleeding and perforations). all patients will have a control colonoscopy 6 months after polypectomy to investigate long-term results.

Eligibility criteria:
inclusion criteria: * patients with non-pedunculated colorectal adenomas who had provided written informed consent exclusion criteria: * known coagulopathy. * polyposis of the alimentary tract. * inflammatory bowel disease. * malignant polyps. * associated diseases in the stage of decompensation

Keywords: cold snare polypectomy hot snare polypectomy сolorectal polyps endoscopic treatment
test-retest reliability, responsiveness and interpretability of cleft-q

Conditions: Cleft Lip and Palate

Summary: the goal of this observational study is to test the questionnaire cleft-q in a population of patients with cleft lip and/or palate. the main questions it aims to answer are: 1. are cleft-q scores reliable over time? 2. can cleft-q detect change following surgical treatment intervention? 3. what is the norm for cleft-q within a control population who do not have cleft lip and/or palate? 4. what is the minimal clinically important change of cleft-q in different subpopulations of cleft lip and/or palate? 5. do changes in cleft-q scores correlate with changes in objective outcomes following a surgical intervention? 6. what are the main expectations that patients express before a surgical intervention? 7. how do patients perceive that the results after surgical interventions meet their expectations? 8. do patients express concepts of importance postoperatively that are not examined by cleft-q? 9. how do healthcare professionals perceive that the use of cleft-q affects clinical decisions and processes? participants will 1. fill out the questionnaire cleft-q twice with a two-week space. 2. before and 1 year after an operation. 3. be interviewed about their experiences related to an operation or using cleft-q. researchers will compare results from the cleft lip and palate population to see if there is a difference between them and a population without cleft lip and palate.


Eligibility criteria:
inclusion criteria: * cleft lip and/or palate * planned secondary surgery of the nose, lips, jaw or to improve speech * can speak and read swedish exclusion criteria: * multiple surgeries at once

Keywords: cleft-q psychometrics test-retest reliability interpretability responsiveness
physical exercise, nutrition supplement and frailty of older population

Conditions: Sarcopenia; Physical Exercise; Nutrition Poor; Elderly

Summary: this study is aimed to explore the effect of physical exercise and nutrition supplement on improving frailty, depressive symptoms, and quality of life in community-dwelling older population.

objective: this study is aimed to explore the effect of physical exercise and nutrition supplement on improving frailty, depressive symptoms, and quality of life in community-dwelling older population. methods: we conduct a quasi-experimental study to measure frailty, depressive symptoms, and quality of life before and after intervention. a total of 120 community-living older adults with frailty identified by fried's phenotype method are assigned to four groups: physical exercise group, nutrition supplements group, physical exercise and nutrition supplements group, and control group. each participants in the assigned group will receive 12 weeks intervention. measurements include frailty (fried's phenotype method), depressive symptoms (geriatric depression scale-15, gds-15), and quality of life (whoqol-bref). data analyses include describe statistics, chi-square test, and analysis of variance. a generalized estimating equations (gee) will be used to examine the effect of physical exercise and nutrition supplement on improving frailty, depressive symptoms, and quality of life.

Eligibility criteria:
inclusion criteria: * older adults aged more than 60 years; * pre-frail stage: must have one item as frailty identified using the fried's phenotype method; * normal cognition: ad8 score less than 2 points; * can communicate with mandarin or taiwanese. exclusion criteria: * incapable of walk independent or using assistive devices (e.g., crutches); * a condition of having an acute disease, hemodialysis, or unable to engage in physical activity; * have history of unstable heart disease such as coronary heart disease, heart failure and hypertension without regular medication; * have regular physical activity (≥150 minutes weekly) such as aerobic dance, swimming, tai chi.
safety, tolerability, pk and pd of intravenous ferric carboxymaltose in infants with iron deficiency anemia

Conditions: Iron Deficiency, Anaemia

Summary: an open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous ferric carboxymaltose (fcm) in infants (0-1 year) with iron deficiency anemia.

a phase ii, open-label, multi-center study with 2 cohorts to evaluate the safety, tolerance, pk, and pd profile of intravenous (iv) fcm in infants 0 to 1 year of age with ida after receiving either a 5.0 mg/kg or 7.5 mg/kg dose of fcm. participants will have a screening evaluation within 14 days of the first dose of study drug. a medically supervised environment is required on day 1 (day of dosing) and for 4 hours post dosing. participants are allowed to be enrolled if satisfying the inclusion and exclusion criteria. participants will return to the study site for additional evaluation and sampling on days 8 (± 2 days), 15 (± 2 days), 22 (± 2 days), and 36 (± 2 days).

Eligibility criteria:
inclusion criteria: 1. male and female participants 0 to 1 year of age, medically indicated for iron replacement, with his/her parent or legal guardian willing and able to sign the informed consent form approved by the irb / independent ethics committee (iec). 2. screening hb ≥7 g/dl to \<10 g/dl. 3. infants with any of the following conditions: * heart failure with ida defined as syndromes of excessive preload, excessive afterload, abnormal rhythm, or decreased contractility * gastrointestinal diseases with acquired short bowel syndrome (due to volvulus, necrotizing enterocolitis from surgical resection or spontaneous intestinal perforation) * gastrointestinal intolerance of oral iron or an unsatisfactory response to oral iron * other conditions associated with ida which in the opinion of the investigator might benefit from administration of fcm exclusion criteria: 1. known history of hypersensitivity reaction to fcm. 2. body weight \<2.5 kg. 3. history of acquired iron overload, hemochromatosis, or other iron accumulation disorders. 4. hemodialysis-dependent chronic kidney disease. 5. history of significant diseases of the liver, hematopoietic system, cardiovascular system, or other conditions which, on the opinion of the investigator, may place a participant at added risk for participation in the study. 6. active infection. 7. anemia due to reasons other than iron deficiency (e.g., hemoglobinopathy vitamin b12 deficiency, or folic acid deficiency). 8. blood transfusion in the 4 weeks prior to consent. 9. administration of an iron-containing product within 14 days of administration of the study article. 10. administration and / or use of an investigational product (drug or device) within 30 days of screening. 11. current participation in another clinical trial. 12. unable to comply with study procedures and assessments.
research study of visilizumab for treatment of glucocorticoid- refractory graft versus host disease

Conditions: Graft-vs-Host Disease

Summary: the purpose of this phase ii study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory graft versus host disease (gvhd). patients diagnosed with gvhd who have not responded satisfactorily to, or are intolerant of, treatment with standard agents will be considered for entry. patients will be allowed to continue on their other immunosuppressive drugs at stable doses during the trial. the research is being conducted at up to 20 clinical research sites in the us.


Eligibility criteria:
* grade ii to iv gvhd * clinical findings: skin thickening, joint contraction, oral ulceration, diarrhea. * history of allogeneic hematopoietic cell transplant (hct). * patients must have failed to respond or clearly progress to previous therapy on or before day +100 posttransplant. * patients must have adequate renal, hepatic, cardiac function and hematologic values
clinical impact of the withdrawal of nitrate in patients with stable angina

Conditions: Stable Angina; Myocardial Ischemia; Quality of Life

Summary: chronic treatment of stable angina with nitrates long and short action is extremely frequent. in clinical practice the most commonly observed is a combination of anti-anginal agents, usually including nitrates fixed in an attempt to improve the quality of life of patients, which is not always met with success. numerous questions and problems are seen with chronic use of oral nitrates. from a practical standpoint, some advocate the withdrawal of medication in stable patients, while many physicians still hesitate to withdraw the medication by the lack of definitive information about its consequences. in this sense there is a rationale for the attempted removal of nitrate fixed these patients, although evidence to support this action have not been adequately evaluated.

the ischemic heart disease remains in recent years as a major cause of mortality in most of the world, and also the disease that consumes more resources in health in industrialized countries. the use of fixed nitrate in patients with stable angina is quite common, but there is a scarcity of studies showing the need for this medication in this class pacientes.este study aims to evaluate the consequences of the withdrawal of fixed nitrate in patients with stable angina class i and ii, hemodynamically stable for the past six months, as the frequency and duration of episodes of angina, silent ischemia and functional capacity by exercise testing, 24-hour holter and measurement of quality of life and adherence to therapy. for this purpose, a randomized blinded multicenter clinical trial was designed to placebo (intervention group) x nitrate (control group) in a follow-up period for 4 months. both groups will receive three evaluations (baseline, 30 days and 120 days) during follow-up.

Eligibility criteria:
inclusion criteria: * patients of both sexes, aged 18 years or above, with coronary artery disease documented by angiography or noninvasive test (scintigraphy) with stable angina functional class i or ii of the canadian cardiothoracic society (ccs), clinically stable for at least six months, using two or more antianginal agents (betablockers or calcium channel antagonist), among them nitrate fixed. exclusion criteria: * patients with residence far from the research center and unable to appropriate follow-up. patients with decompensated heart failure symptoms or class iii or iv new york heart association (nyha), poorly controlled hypertension (bp greater than 160/90 mmhg), patients unable to walk or perform stress test and ecg interpretable. also excluded were patients in the exercise test pre-randomization present significant alterations.
tap-block in abdominal aortic surgery

Conditions: Aortic Aneurysm, Abdominal

Summary: the primary outcome of this study was the evaluation of the efficacy of tap block on pain intensity following open abdominal aortic surgery.


Eligibility criteria:
inclusion criteria: * open abdominal aortic surgery (aneurysm or aortobifemoral bypass) * person who has given his written consent exclusion criteria: * emergency surgery * patient with infection * use of opioids in the long term * history of chronic pain * higher functions incompatible with the functioning of the pca * patients under guardianship

Keywords: analgesia tap-block
diathermy compared with sham diathermy in doms management

Conditions: Musculoskeletal Diseases

Summary: to investigate the effect of hand massage, switched on diathermy or sham/switched off diathermy on doms in a group of athletes suffering doms after a ski mountaineering race.

this study examine doms in athletes following a ski mountaineering race, pain measured with numbering pain rating scale nprs and perceived global improvement (pgic) after treatment have been measured after a massage treatment, a diathermy treatment and a sham diathermy treatment.

Eligibility criteria:
inclusion criteria: - healthy patients who complaints about d.o.m.s. after a skimountaneering race exclusion criteria: - patient who complain of pathology such trauma or declaring consuming drugs for pain management where excluded from the study.
topical anesthesia in small gauge vitrectomy

Conditions: Pain

Summary: the use of topical anesthetics is a non invasive option avoiding local or general anesthesia in small gauge vitrectomy without causing intolerable pain


Eligibility criteria:
inclusion criteria: * pseudofaquic or faquic, * male or female, * 18 to 80 years, * primary vitrectomy exclusion criteria: * combined surgery * non cooperative patients

Keywords: pain scale of pain